Patent EP0178140A2 successfully refreshed from Google Patents.
EP0178140A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Transdermal therapeutic systems for the administration of nalozone, naltrexone and nalbuphine
Assignee: Alza Corp
•
Filing: 1985-10-07
•
Granted: —
•
Expires: 2005-10-07
Abstract
Abstract A method for transdermal delivery of naloxone, naltrexone and nalbuphine base through intact skin is described. Preferred embodiments of transdermal therapeutic systems for delivering these drugs and polyethylene glycol monolaurate employ an ethylene vinylacetate matrix containing drug base at a concentration above saturation and polyethylene glycol monolaurate below unit activity. Polyethylene glycol monolaurate is disclosed as a permeation enhancer for the base form of these drugs and is preferably delivered simultaneously with the drug.
Inventors
- 👤 Yu-Ling Cheng
- 👤 Leslie T. Chun
- 👤 David Enscore
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-10-29 22:19
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/70; A61K9/7023; A61K9/703; A61K9/7084; A61K31/00; A61K31/33; A61K31/395; A61K31/435; A61K31/47; A61K31/485; A61K47/00; A61K47/06; A61K47/08; A61K47/14; A61K9/0012; A61K9/0014
Claims Analysis
Total Claims: 13
Claim 1
Independent Claim
39 words
A composition of matter for the transdermal administration of a drug selected from naloxone, naltrexone and nalbuphine and mixtures thereof, comprising matrix containing the base form of the drug and a skin permeation enhancing amount of polyethylene glycol monolaurate.
Claim 2
Dependent Claim
39 words
A composition of matter for the transdermal administration of a drug selected from naloxone, naltrexone and nalbuphine and mixtures thereof, comprising matrix containing the base form of the drug and a skin permeation enhancing amount of polyethylene glycol monolaurate.
Claim 3
Dependent Claim
25 words
A composition as claimed in claim 1 wherein said drug base is present in an amount in excess of its saturation concentration in the matrix.
Claim 4
Dependent Claim
25 words
A composition as claimed in claim 1 or claim 2 wherein said polyethylene glycol monolaurate is present at an activity no greater than about 0.60.
Claim 5
Dependent Claim
16 words
A composition as claimed in any preceding claim wherein said matrix comprises an ethylene vinylacetate polymer.
Claim 6
Dependent Claim
17 words
A composition as claimed in claim 4 wherein said ethylene vinylacetate polymer comprises 28 to 60% vinylacetate.
Claim 7
Dependent Claim
26 words
A composition as claimed in claim 4 or claim 5 wherein the average molecular weight of the polyethylene glycol component is of the order of 200.
Claim 8
Dependent Claim
17 words
A composition as claimed in any preceding claim wherein the source of drug is at unit activity.
Claim 9
Dependent Claim
17 words
A composition as claimed in any preceding claim wherein said polyethylene glycol monolauroleate is below unit activity.
Claim 10
Dependent Claim
48 words
A transdermal therapeutic system comprising the composition as claimed in any preceding claim in combination with: a) an occlusive backing behind the skin distal surface of said reservoir composition and b) means for maintaining said reservoir composition in drug and polyethylene glycol monolaurate transferring relationship to human skin.
Claim 11
Dependent Claim
40 words
A system as claimed in claim 9 wherein said occlusive bcking extends beyond the periphery of said composition and said means for maintaining the system on the skin comprises an adhesive overlay extending beyond the periphery of said occlusive backing.
Claim 12
Independent Claim
32 words
A system as claimed in either of claims 9 and 10, wherein drug is delivered through the skin at a rate of about 20-40 µg/hr/cm 2 for an extended period of time.
Claim 13
Independent Claim
31 words
A system as claimed in any one of claims 9 to 11 wherein the initial activity of said PEGML in said source is within the range of about 0.25 - 0.60.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.